References
- 1. Rodriguez M. (1997) Multiple sclerosis:Insights into molecular pathogenesis and therapy. Mayo Clinic Proc 1997; 72:663-4.
- 2. Kemp K, Redondo J, Hares K, &Rice C, Scolding N, Wilkins A. (2016) Oxidative injury in multiple sclerosis cerebellar grey matter. Brain Res. 2016 Apr 14. pii: S0006-8993(16)30236-0. doi: 10.1016/j. brainres.2016.04.027. [Epub ahead of print]
- 3. Beckman JS, Koppenol WH. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol; 271:C1424-C1437.
- 4. Carvalho AN, Firuzi O, Gama MJ, van Horssen J, Saso L. (2016) Oxidative stress and antioxidants in neurological diseases: is there still hope? Curr Drug Targets. Vol: 17 DOI: 10.2174/138945011766616040112051410.2174/1389450117666160401120514
- 5. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R et al. (1997) Prevention of experimental allergic encephalo-myelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 1997; 94:2528-2533.10.1073/pnas.94.6.2528
- 6. Zabaleta ME, Bianco NE, De Sanctis JB. (1998) Serum nitrotyrosine levels in patients with multiple sclerosis: Relationship with clinical activity. Medical Science Research 1998; 26:407-408.
- 7. Squadrito GL, Cueto R, Splenser AE, Valvanidis A, Zhang H, Uppu RM et al. (2000) Reaction of uric acid with peroxinitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376 (2):333-337.
- 8. Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, Postiglione E, De Luca Picione C, Vastola M, Maniscalco GT, Palladino R, Brescia Morra V. (2015) Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. J Neurol. 2015;262(4):961-7
- 9. Ashtari F, Bahar M, Aghaei M, Zahed A. (2013) Serum uric acid level in patients with relapsing-remitting multiple sclerosis. J Clin Neurosci. 2013 May;20(5):676-8.
- 10. Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D’Onghia M, Luciannatelli E, Paolicelli D, Livrea P, Trojano M. (2012) Low serum urate levels are associated to female gender in multiple sclerosis patients. PLoS One. 2012;7(7):e40608.
- 11. Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J.(2012) Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res. 2012 Mar;34(2):163-71.
- 12. Toncev G, Milicic S, Toncev S, Samardzic G. (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 2002; 9:221-226.10.1046/j.1468-1331.2002.00384.x
- 13. Drulović J, Dujmović I, Stojsavljević N, Mesaroš S, Andjelković S, Miljković Dj, et al. (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol Feb 2001; 248(2):121-6.
- 14. Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, et al. (2002) Serum uric acid and multiple sclerosis. Nerol Sci 2002; 23:183-188.
- 15. Pakpoor J, Seminog OO, Ramagopalan SV, Goldacre MJ. (2015) Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies. BMC Neurol. 2015 Feb 28;15:16.
- 16. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaundrhy I, et al. (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 95, pp. 675-680.
- 17. Dhib-Jalbut S. (1997) Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 1997; 3:397-401.10.1177/135245859700300609
- 18. Arnason BG, Dayal A, Qu ZX, Jensen MA, Genc K, Reder AT (1996) Mechanisms of action of interferon beta in multiple sclerosis. Springer Semin Immunopathol 1996; 18:125-148.10.1007/BF00792613
- 19. Stuve O, Dooley NP, Uhm JH Antel Jp, Francis GS, Williams G et al. (1996) Intrferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-863.
- 20. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendrop S, Lehmann P, Alam J. (1996) Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40:618-627.
- 21. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1):121-7.10.1002/ana.1032
- 22. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1442-52.
- 23. Kanabrocki EL, Third JLH, Ryan MD, Nemchausky BA, Shirazi P, Schebing LE, et al. (2000) Circadian relationship of serum uric acid and nitric oxide. J Am Med Asssoc 2000; 283:2240-1.
- 24. Тončev G, Miletic Drakulic S, Knezevic Z.(2007) Treatment with interferon beta 1b (Betaferon) and serum uric acid levels: two year follow up. Mult Scler; 13 (Suppl 2), S7-S273, p305.
- 25. Massa J, O’Reilly E, Munger KL, Delorenze GN, Ascherio A. (2009) Serum uric acid and risk of multiple sclerosis. J Neurol. 2009 Oct;256(10):1643-8.
- 26. Koprowsky H, Spitsin S, Hooper C. (2001) Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxinitrite. Ann Neurol 2001; 49 (1):139.10.1002/1531-8249(200101)49:1<;139::AID-ANA28>3.0.CO;2-A
- 27. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowski H. (2001) Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 2001; 7(5):313-9.10.1177/135245850100700507
- 28. Constatinescu CS, Freitag P, Kappos L. (1999) Increase in serum levels of uric acid, an endogenous antioxidant, in treatment with glatiramer acetate (GAA) for multiple sclerosis. Mult Scler 1999; 5(Suppl 1): S104.
- 29. Toncev G, Milicic S, Toncev S, Samardzic G. (2002) High-dose methylprednisolone therap in multiple sclerosis increses serum uric acid levels. Clin Chem Lam Med 2002; 5:505-508.